ID

13630

Description

Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors https://de.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors http://www.ncbi.nlm.nih.gov/pubmed/19097774

Link

https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors

Keywords

Versions (1)
  1. 2/22/16 2/22/16 - Martin Dugas
Copyright Holder

Eisenhauer EA

Uploaded on

February 22, 2016

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

RECIST

German English

Response Evaluation Criteria in Solid Tumors

1 forms  
Response Evaluation Criteria in Solid Tumors
Description

Response Evaluation Criteria in Solid Tumors

Alias
UMLS CUI-1
C1709926
Evaluation of target lesions
Description

Evaluation of target lesions

Data type

text

Alias
UMLS CUI [1]
C2986558
Evaluation of non-target lesions
Description

Evaluation of non-target lesions

Data type

text

Alias
UMLS CUI [1]
C2986559
Best overall response
Description

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria - Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be classified as having “symptomatic deterioration”. Every effort should be made to document the objective progression even after discontinuation of treatment. - In some circumstances it may be difficult to distinguish residual disease from normal tissue. When the evaluation of complete response depends on this determination, it is recommended that the residual lesion be investigated (fine needle aspirate/biopsy) to confirm the complete response status.

Data type

text

Alias
UMLS CUI [1]
C2986560
Duration of stable disease
Description

SD is measured from the start of the treatment until the criteria for disease progression are met, taking as reference the smallest measurements recorded since the treatment started. The clinical relevance of the duration of SD varies for different tumor types and grades. Therefore, it is highly recommended that the protocol specify the minimal time interval required between two measurements for determination of SD. This time interval should take into account the expected clinical benefit that such a status may bring to the population under study.

Data type

durationDatetime

Alias
UMLS CUI [1,1]
C0677946
UMLS CUI [1,2]
C0449238
Back to the top of the page

Similar models

Response Evaluation Criteria in Solid Tumors

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Response Evaluation Criteria in Solid Tumors
C1709926 (UMLS CUI-1)
Item
Evaluation of target lesions
text
C2986558 (UMLS CUI [1])
Evaluation of target lesions
Code List
Evaluation of target lesions
CL Item
Complete Response: Disappearance of all target lesions (CR)
C1275810 (UMLS CUI-1)
CL Item
Partial Response: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD (PR)
C1275833 (UMLS CUI-1)
CL Item
Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started (SD)
C0677946 (UMLS CUI-1)
CL Item
Progressive Disease: At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (PD)
C1335499 (UMLS CUI-1)
Item
Evaluation of non-target lesions
text
C2986559 (UMLS CUI [1])
Evaluation of non-target lesions
Code List
Evaluation of non-target lesions
CL Item
Complete Response: Disappearance of all non-target lesions and normalization of tumor marker level (CR)
C1275810 (UMLS CUI-1)
CL Item
Incomplete Response/ Stable Disease: Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits (SD)
C0677946 (UMLS CUI-1)
CL Item
Progressive Disease: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions (PD)
C1335499 (UMLS CUI-1)
Item
Best overall response
text
C2986560 (UMLS CUI [1])
Best overall response
Code List
Best overall response
CL Item
Complete Response (CR)
C1275810 (UMLS CUI-1)
CL Item
Partial Response (PR)
C1275833 (UMLS CUI-1)
CL Item
Stable Disease (SD)
C0677946 (UMLS CUI-1)
CL Item
Progressive Disease (PD)
C1335499 (UMLS CUI-1)
Duration of stable disease
Item
Duration of stable disease
durationDatetime
C0677946 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial